Influence of Skin Subjective Symptoms on Sleep Quality in Patients with Cutaneous Disorders: A Study of 2871 Subjects.

INTRODUCTION: Previous studies showed more sleep disturbance (SD) in patients with cutaneous disorders (CD). During CD, unpleasant subjective symptoms [USS], such as itch, pain and others (tingling, burning, or tightness) have a negative influence on sleep quality. This study aims to evaluate the prevalence of SD in CD patients and to identify the influence of itch, pain and other unpleasant sensations on SD.
MATERIALS AND METHODS: An international, anonymized real-life survey was conducted with individuals [18-75 years], with physician-confirmed CD, or without CD. The 25 items covered sociodemographic characteristics, feeling of overall sleep quality and skin unpleasant sensations. Severity of SD and unpleasant sensations were assessed using a 10-cm Visual Analogue Scale (VAS).
RESULTS: From 3834 analyzed questionnaires, 2871 (67.3%) were in the CD group and 863 (32.7%) in the control group. Patients with CD had significantly more SD (71.2% vs 32.7% in the control group, p<0.0001). CD patients without any reported unpleasant sensation were at higher risk for SD than control subjects (OR 1,362 [95% CI 1.975-2.405] p=0.0013). SS were highly associated with SD (OR 1.641 [95% CI 1.393-1.933] p<0.0001). Pruritus, pain and intermediate sensations were significant predictors of SD, with odds ratios of 1.670, 1.625 and 1.326, respectively. VAS sleep scores were strongly associated with pruritus (r: 0.25, p<0.0001) and pain (r: 0.25 p<0.0001) severity ratings. DISCUSSION: SD is a common problem for patients with CD. Patients with subjective symptoms suffer more from SD, suggesting that they are aggravating factors, but are likely not the only reason for SD in CD patients. We found that during CD, intermediate sensations also contribute to SD. Despite some limitations and the potential bias due to the study design, our results confirm for the first time on an international level the influence of subjective symptoms on sleep quality in patients with CD.

Introduction

Sleep, which occupies approximately one-third of the lives of human beings, is essential for mental and physical health and well-being.1 Sleep disturbances (SDs) are distressing and disabling conditions that are frequently reported in chronic medical illnesses with significant quality-of-life impairment.2,3 Previous studies have shown more SD in patients with cutaneous disorders (CD),4 such as psoriasis,5–8 atopic dermatitis,9–11 vitiligo,12,13 acne,14 urticaria,15,16 prurigo nodularis,17 hidradenitis suppurativa18 and lichen planus.19 SD can aggravate the underlying CD and cause decreased health-related quality of life (HRQoL).5,20,21 SDs are often under-recognized and under-reported in patients with CD because of the absence of systematic or specific questioning by dermatologists. The pathogenesis of SD in patients with CD is complex and multifactorial. Unpleasant subjective symptoms such as itch and pain are known to have a negative influence on the sleep quality of CD patients, causing both difficulty in falling asleep and frequent awakenings from sleep.4,5,18,22–29 In addition to pruritus and pain, patients with CD can suffer from other unpleasant symptoms, such as tingling, burning or tightness.30 The current state of knowledge about the influence of these other unpleasant sensations on SD in patients with CD is limited and not fully understood. The aim of the present study was to evaluate the prevalence of sleep disturbance in CD patients and to identify the influence of itch, pain and other unpleasant sensations on SD.

Materials and Methods

An international, anonymized survey was conducted from December 2018 to January 2019 via a digital questionnaire in France, Brazil, China, Russia and the USA on participants with self-reported dermatosis (respondents reported that the diagnosis had been confirmed by a physician) or without dermatosis (control-group), using a representative sample of the general adult population aged between 18 and 75 years of age. The survey was conducted by means of local Internet databases of users who agreed to participate in surveys. It complied with local data protection laws and used completely anonymized data. No participant refused to participate. The evaluation was conducted in accordance with the relevant ethical guidelines.

In fact, as this study did not involve any patient contact and was completely anonymous, approval from the ethical review board was not necessary. Each subject was informed of the nature of the questionnaire and confirmed his or her agreement before being able to respond. The GPRD was respected.

The CD group was defined as the individuals with at least one self-reported dermatosis. Subjects had to confirm that their dermatosis was clinically confirmed by a physician. Exclusion criteria included a non-physician confirmed dermatosis and age greater than 75 years.

The questionnaire was composed of items covering the following: 1) Sociodemographic characteristics. 2) Individual’s subjective feeling of overall sleep quality, that was measured using a 10-cm Sleep Disturbance Visual Analogue Scale (SD-VAS). Scores of the SD-VAS ranged from 0 (no SD) to 10 points (worst SD). SD VAS scoring was categorized as mild (>0 to <3 points), moderate (≥3 to <7 points) and severe or very severe SD (≥7 to 10 points). The SD-VAS is a sensitive, reproducible, reliable and validated measure31 for the evaluation of sleep quality. Results of SD-VAS data are presented as 95% confidence intervals for the means. 3) Presence of skin unpleasant sensations, such as pain, itch, tingling, burning, or tightness. Three standardized 10-point visual analogue scales (VAS) were used to measure the intensity of itch, pain, and intermediate sensations (tingling, numbness, burning, and tightness); an intensity of 0 meant no symptoms, and 10 indicated the worst possible imaginable sensations.

Based on clinical evaluation, male and female patients were divided into four clinical groups, considering the presence or absence of symptoms and the type of symptoms.

1. Absence of skin unpleasant sensation (pruritus, pain, burning, tightness, tingling, numbness) (Intermediate sensations VAS Scoring, Itch VAS scoring and Pain VAS scoring = 0).

2. Presence of intermediate sensations without pruritus or pain (Itch VAS scoring and Pain VAS scoring = 0).

3. Greater feeling of pruritus associated or not with pain and intermediate sensations (the intensity of pruritus evaluated by VAS is greater than that of pain).

4. Greater feeling of pain associated or not with pruritus and intermediate sensations (the intensity of pain evaluated by VAS is greater than that of pruritus). Control population included subjects who had no subjective symptoms (no burning, tightness, tingling, numbness, pruritus and pain).

Data Analyses

Statistical analysis was performed using Stata 7.0 (Stata corporation, College Station, TX, USA). Data concerning adult individuals between 18 and 75 years of age with at least one dermatosis were extracted from the survey database. Quantitative variables are expressed as the means and standard deviations.

Qualitative variables are expressed as frequencies and percentages. Bivariate analyses involving categorical or qualitative variables were carried out with chi-square statistics. Quantitative variables were compared using the Student’s test. The presence of a relationship between quantitative features was tested using Pearson’s correlation coefficient for parameters consistent with a normal distribution and Spearman correlation coefficient in cases of non-compliance with a normal distribution. A p-value of 0.05 was considered to indicate a statistically significant difference.

Results

Demographic Characteristics of Patients with Cutaneous Disorders

A total of 11,000 individuals participated in the survey, and data from 3834 of them were usable for statistical analysis: 2871 (67.3%) from the CD group and 863 (32.7%) from the control-group (Figure 1). The recruited patient group with CD [Acne (n=1044); Psoriasis (n=163); Atopic dermatitis (n=254); Contact dermatitis (n=147); Rosacea (n=201); Vitiligo (n=50); Seborrheic dermatitis (n= 195); Scalp disorders (n=216); Photo dermatosis (n=422); Other skin disorders (n=179)] consisted of 1306 males and 1565 females (age 39.4±14.5 years, range 18–74 years). Details regarding the patient demographics of the study sample are summarized in Table 1.

Figure 1

Study population.

Table 1

Demographic Data of Cutaneous Disorders (CD) Patients and Control Subjects

		Patient Group with CD,N (%)	Control Subjects,N (%)	p
	Total	2871	863
Gender	Male	1306 (45.5)	529 (61.3)	0.814292
	Female	1565 (54.5)	334 (38.7)
Age	Mean	39.44	44,68	8.745E-18
	18–29 years	903 (31.5)	167 (19.4)
	30–39 years	656 (22.8)	179 (20.7)
	40–49 years	588 (20.5)	188 (21.8)
	50–59 years	378 (13.2)	149 (17.3)
	60–64 years	164 (5.7)	64 (7.4)
	>60 years	346(6.3)	180 (13.4)
Phototype	Phototype I	353 (12.3)	100 (11.6)
	Phototype II	786 (27.4)	220 (25.5)
	Phototype III	1041 (36.3)	334 (38.7)
	Phototype IV	448 (15.6)	149 (17.3)
	Phototype V	110 (3.8)	30 (3.5)
	Phototype VI	133 (4.6)	30 (3.5)

The 2871 subjects suffering from skin disorders were individualized into 4 groups, considering the presence or absence of symptoms and the type of symptom.

- A total of 182 (6.3%) patients felt no pruritus, no pain and no intermediate sensation (burnings, tightness, tingling, numbness) (Intermediate sensations VAS Scoring, Itch VAS scoring and Pain VAS scoring = 0).

- A total of 205 (7.1%) subjects felt intermediate sensations without pruritus and pain (Intermediate sensations VAS Scoring: from 0.1 to 10, Itch VAS scoring and Pain VAS scoring = 0).

- A total of 2325 (81%) subjects felt more significant pruritus associated or not with pain and/or intermediate sensations (Itch VAS scoring from 0.1 to 10 and higher than Pain VAS scoring).

- A total of 159 (5.5%) subjects felt more important pain associated or not with pruritus and intermediate sensations (Pain VAS scoring from 0.1 to 10 and higher than Itch VAS scoring).

Information on the prevalence rates of pruritus, pain and intermediate sensations for each skin disease is provided in Table 2.

Table 2

Prevalence of Pruritus, Pain and Intermediate Sensations Among Cutaneous Disorders Group

	Pruritus	Pain	IntermediateSensations	Asymptomatic
Acne n=1044 (36.36%)	829 (79.4%)	59 (5.7%)	79 (7.6%)	77 (7.4%)
Psoriasis n=163 (5.67%)	126 (77.3%)	13 (8.0%)	9 (5.5%)	15 (9.2%)
Atopic dermatitis n=254 (8;84%)	229 (90.2%)	9 (3.5%)	9 (3.5%)	7 (2.8%)
Contact dermatitis n=147 (5.12%)	130 (88.4%)	7 (4.8%)	3 (2.0%)	7 (4.8%)
Rosacea n=201 (7%)	144 (71.6%)	13 (6.5%)	22 (10.9%)	22 (10.9%)
Vitiligo n=50 (1.74%)	40 (80.0%)	1 (2.0%)	5 (10.0%)	4 (8.0%)
Seborrheic dermatitis n=195 (6.79%)	162 (83.1%)	8 (8.0%)	18 (9.2%)	7 (3.6%)
Scalp disorders n=216 (7.52%)	181 (83.8%)	9 (4.2%)	20 (9.3%)	6 (2.8%)
Photodermatosis n=422 (14.70%)	344 (81.5%)	28 (6.6%)	26 (6.2%)	24 (5.7%)
Other skin disorders n=179 (6.23%)	140 (78.2%)	12 (6.7%)	14 (7.8%)	13 (7.3%)

Prevalence and Intensity of Sleep Disorders

Sociodemographic and clinical characteristics of patients from the CD group and the control group are summarized in Table 3. Patients suffering from CD were significantly younger than the control ones (39.41 ± 14, versus 43.73 ± 14.89, p: 2.42 E-06). We found a significantly higher prevalence of SD among patients with CD (71,2% vs 32.7% in the patient control-group, p: 646E-88). Patients with CD were at a significantly increased risk for SD when compared with control subjects (OR 2.179 [95% CI 1.128–1.644] p<0.0001). Patients with asymptomatic CD were at a significantly increased risk for SD when compared with control subjects (OR 1.362 [95% CI 1.975–2.405] p: 0.0013). However, there was no difference in the severity of SD between patients suffering from asymptomatic CD and control subjects (3.56 ± 2.35 vs 3.54 ± 2.32, p: 0.92).

Table 3

Sociodemographic and Clinical Characteristics of Patients with and without Sleep Disorders (SD)

		Patients with SDn=2871	Patient Control Group without SD n=863	P value
Skin=disorders	Total	2045 (71.2%)	282 (32.7%)	6.46E-88
	Mild (>0 to <3 points)	795 (27.7%)	132 (15.3%)	1.78E-31
	Moderate (≥3 to <7 points)	919 (32%)	128 (14.8%)	3.22E-19
	Severe or very severe (≥7 to 10 points)	331 (11.5%)	22 (2.5%)	4.22E-21
Gender	Male	907 (69.4%)	161 (30.4%)	2.16E-48
	Female	1138 (72.7%)	121 (36.2%)	4.08E-33
Age	Mean	39.41 ± 14.43	43.73 ± 14.89	2.42 E-06
	18–29 years	631 (69.90%)	60 (35.9%)	1.25E-13
	30–39 years	463 (70.60%)	58 (32.4%)	5.12E-17
	40–49 years	453 (77.00%)	64 (34%)	1.69E-23
	50–59 years	263 (69.60%)	47 (31.5%)	3.4E-12
	>60 years	235 (67.4%)	53 (29.4%)	1.21E-13
Phototype	Phototype I	261 (73.9%)	26 (26%)	6.99E-15
	Phototype II	578 (73.5%)	73 (33.2%)	2.26E-24
	Phototype III	733 (70.4%)	119 (35.6%)	6.42E-26
	Phototype IV	302 (67.4%)	51 (34.2%)	1.39E-09
	Phototype V	71 (64.5%)	6 (20%)	0.00229
	Phototype VI	100 (75.2%)	7 (23.3%)	3.12E-05

The prevalence of SD was not significantly different between males and females (69.4% in males and 72.7% in females, p: 0.49). The prevalence of SD was significantly higher after 40 years in females (537/1138 47.2% in women versus 324/907 35.7% in men p: 1.81E-7) (Table 4).

Table 4

Sleep Disturbance Visual Analogue Scale (SD-VAS) of Patients with Sleep Disturbance

		SDN(%)	SD VASScoresMean, Standard Deviation (SD)	SD VASMild(>0 to <3 Points)	SD VASModerate(≥3 to <7 Points)	SD VASSevere or Very Severe(≥7 to 10 Points)
Cutaneous disorders	Total n=2871	2045 (71.2)	4.13 ± 2.51	795 (38.9%)	919 (44.9%)	331 (16.9%)
Control	Total n=863	282 (32.7)	3.54 ± 2.32	132 (46.8%	128 (45.4%)	22 (7.8%)
Category of patients	Symptomatic n=2689	1964 (73)	4.15 ± 2.51	756 (38.5%)	884 (45%)	324 (16.5%)
	Pruritis n=2325	1728 (74.3)	4.14 ± 2.51	676 (39.1%)	769 (44.5%)	283 (16.4%)
	Painn =159	115 (72.3)	4.85 ± 2.55	27 (23.5%)	62 (53.9%)	26 (22.6%)
	Intermediate sensations n=205	121 (59)	3.72 ± 2.42	53 (43.8%)	53 (43.8%)	15 (12.4%)
	Asymptomatic n=182	81 (44.5)	3.56+/2.35	39 (48.1%)	35 (43.2%)	7 (8.6%)
Type of Skin Disorders	Acnen=1044	715 (68.5)	4.02 ± 2.51	282 (39.4%)	323 (45.2%)	110 (15.4%)
	Psoriasis n=163	114 (69.9)	3.92 ± 2.40	50 (43.9%)	50 (43.9%)	14 (12.3%)
	Atopic dermatitis n=254	183 (72)	4.01 ± 2.49	77 (42.1%)	81 (44.3%)	25 (13.7%)
	Contact dermatitis n=147	116 (78.9)	3.90 ± 2.33	47 (40.5%)	56 (48.3%)	13 (11.2%)
	Rosacea n=201	139 (69.2)	4.20+/2.53	55 (39.6%)	61 (43.9%)	23 (16.5%)
	Vitiligo n=50	41 (82.0)	4.59 ± 2.86	15 (36.6%)	16 (39.0%)	10 (24.4%)
	Seborrheic dermatitis n=195	139 (71.3)	4.05 ± 2.47	54 (38.8%)	61 (43.9%)	24 (17.3%)
	Scalp disorders n=216	168 (77.8)	3.97 ± 2.48	70 (41.7%)	76 (45.2%)	22 (13.1%)
	Photodermatosis n=422	319 (75.6)	4.70 ± 2.55	97 (30.4%)	151 (47.3%)	71 (22.3%)
	Others skin disordersn=179	111 (62.0)	3.93 ± 2.44	48 (43.2%)	44 (39.6%)	19 (17.1%)
Gender	Male n=1306	907 (69.4)	3.84 ± 2.41	393 (43.3%)	401 (44.2%)	113 (12.5%)
	Female n=1565	1138 (72.7)	4.36 ± 2.56	402 (35.3%)	518 (45.5%)	218 (19.2%)
Age	18–29 years n=903	631 (69.9)	3.98 ± 2.33	236 (37.4%)	313 (49.6%)	82 (13.0%)
	30–39 years n=656	463 (70.6)	3.98 ± 2.40	184 (39.7%)	222 (47.9%)	57 (12.3%)
	40–49 years n=588	453 (77.0)	4.17 ± 2.58	188 (41.5%)	180 (39.7%)	85 (18.8%)
	50–59 years n=37	263 (69.6)	4.49 ± 2.81	99 (37.6%)	104 (39.5%)	60 (22.8%)
	>60 yearsn=346	235 (67.9)	4.35 ± 2.62	88 (37.4%)	100 (42.6%)	47 (20.0%)

The severity of SD was significantly higher in subjects suffering from CD than in controls (4.13 ± 2.51 if dermatosis versus 3.54 ± 2.32 for control people, p=0.0019). The severity of SD was significantly higher in females (4.36 ± 2.56 versus 3.84 ± 2.41 1.85 E-6).

Symptom Predictors of Sleep Disturbance

The Presence of Subjective Symptoms Was Highly Associated with SD (Adjusted HR) 1.641 ([95% CI 1.393–1.933], p<0.0001)

Pruritus, skin pain and intermediate sensations are significant predictors of sleep disturbance, with odds ratios of 1.670 [95% CI 1.417–1.967], p<0.0001), 1.625 [95% CI 1.345–1.962], p<0.0001) and 1.326 [95% CI 1.087–1.617], p<0.0001), respectively.

The prevalence of SD was not significantly different in people suffering from itching compared to those suffering from pain (74.3% versus 72.3%, p: 0.93). The presence of SD in people suffering from pruritus was significantly greater than in those with intermediate sensations (74.3% versus 59%, p: 0.0005). However, the prevalence of SD was not significantly different in people suffering from pain and in those with intermediate sensations (72.3% versus 59%, p: 0.18).

The severity of SD in case of subjective symptoms was significantly higher than the severity of SD in the absence of symptoms (4.15 ± 2.51 vs 3.56 +/2.35, p: 0.03). The intensity of SD was higher in people suffering from pain compared to those suffering from pruritus (4.85 ± 2.55 vs 4.14 ± 2.51, p: 0.003). There was no difference in the intensity of SD between patients suffering from pruritus and those suffering from intermediate sensations according to the Visual Analogue Scale (4.14 ± 2.51 vs 3.72 ± 2.42, p: 0.07).

VAS sleep disturbance scores were strongly associated with increased pruritus severity ratings (r: 0.25, p: 6.02 E-27) and pain (r: 0.25, p: 7.93E-21) (Figures 2 and 3).

Figure 2

Correlation of the intensity of pruritus and the degree of severity disturbance.

Figure 3

Correlation of the intensity of pain and the degree of sleep disturbance.

Discussion

The data from this international, anonymized internet questionnaire conducted with almost 2871 participants provided information aimed at assessing sleep disturbance in patients with cutaneous disorders.

Our study shows that SD is a common problem for patients who have CD, with a high frequency of SD (71.2% versus 32.7% in the control population). In our study, the prevalence of SD in the control population was consistent with that reported in the general population by Soldatos et al,32 who established an SD prevalence of 31.6% in a study carried out on 35,327 subjects from 10 countries. The severity of SD assessed with the Sleep Disturbance Visual Analogue Scale (SD-VAS) was significantly greater in patients with CD (4.13418 ± 2.51 versus 3.54 ± 2.32 in control individuals, p: 0.0019). Our study does not report a higher prevalence in women at all ages, as it has been frequently reported.1,3 However, we highlighted a higher prevalence of SD after 40 years in females than in males (47, 2% versus 35.7%). The increase in the prevalence of SD in females over the age of 40 can be explained by menopause and the per year increasing prevalence of multimorbidities and psychosocial factors affecting sleep.33

The pathogenesis of sleep disorders during CD is multifactorial and can be explained by the direct effects of inflammation, affective disorders34 and comorbid psychological conditions35 frequently found in patients suffering from CD.36 Skin plays an important role in proper sleep activity, including deficits in thermoregulatory mechanisms, body temperature and sleep onset.35,37,38 SD, especially with regard to chronicity, can complicate the course of CD or contribute to the aggravation of dermatological symptoms.4,11,18,24

Stress is a well-known factor that can trigger or enhance CD such as psoriasis, and that can cause a majoration of pruritus, pain or skin inflammation. It can as well have a negative influence on sleep quality, and cause SD. In their review, Chen et al39 highlight a very likely “brain-skin connection”, that involves many stress mediators and effector cells, such as central and skin peripheral hypothalamic-pituitary-adrenal axis, sympathetic-adrenal medullary axis, substance P and neurotrophins.

Indeed, just like the brain has the ability to secrete neromediators in response to stress, there also is a skin peripheral stress response system, which involves cutaneous effector cells (like mast cells or dermal fibroblasts) that have the ability to secrete stress neuromediators.

We found a high prevalence of SD in CD patients without subjective skin symptoms (such as pruritus, pain and intermediate sensations), which suggests that these symptoms are aggravating factors but are unlikely the only reason for SD in patients with CD. Pruritus severity was found to be the primary predictor of sleep quality, and pain severity was the second strongest predictor of sleep interference. Our study presents evidence that pain and pruritus severity correlate negatively with sleep quality. Pain and pruritus both have an antagonistic relationship and share many similarities, including central sensitization processes and a neuropathic component.40–42 Pruritus and pain can significantly impair the quality of life and sleep of patients.11,28 In our study, we found that intermediate sensations also contributed to sleep disruption in patients with skin conditions. Patients who suffer from such sensations struggle to find the appropriate word for the description, which explains the difficulties in the individualization of these symptoms. Apart from the dermatological symptoms, other factors are likely to play an important role in the onset of SD, such as skin inflammation, as suggested by a recent study which established that patients with inflammatory skin disorders report significantly more fatigue and have higher odds of insomnia compared to patients with noninflammatory skin cancers.11

Pathogenesis of SD during chronic inflammation in the course of CD is linked to the activation of microglial cells and astrocytes in brain regions involved in sleep and circadian regulation.11,43,44 Interleukin-1β and tumor necrosis factor (TNF) are characterized by their actions of sleep regulation45 and can lead to symptoms associated with sleep loss, such as sleepiness, fatigue, and poor cognition.46 Sleep disturbance itself can have many negative consequences on CD, badly impacting the integrity and composition of the skin.47 Alterations in skin barrier function may enhance itch by facilitating the entry of pruritogens.48 Acute sleep deprivation has been shown to intensify inflammation of psoriasis in animal studies.49 Furthermore, in the event of dysbiosis which is a dysregulation of the skin microbiota (including bacteria, fungi and viruses) associated with CD, pathogens release proteases, which may disrupt the epidermal barrier. Delta-toxin causes mast cell degranulation, which prompt inflammation and itching.50

Sleep disturbance has deleterious effects on health, including significant quality-of-life impairments, impacts on work and school productivity, driving or transportation accidents due to daytime somnolence, irritability, and poor concentration. SD can contribute to changes in eating habits, with an increased risk of medical comorbidities (obesity, diabetes, hypertension, metabolic syndrome, and cardiovascular disease) and depression.51–57

Limitations

Our study has several limitations. Our sample is a representative group of subjects who consented to take the time to participate in the survey and may be more involved concerning their disease.

Second, it would have been helpful to use a validated instrument to evaluate sleep or an objective measurement of sleep quality (ie, polysomnography and actigraphy). Third, the questionnaire did not detail the existence of associated comorbidities, particularly psychological symptoms, such as anxiety or depression, which can also influence sleep.

Conclusion

Despite these limitations and the potential bias due to the internet study design, our results confirm, for the first time and on a large international level, the influence of subjective skin symptoms on sleep quality in patients with CD. We reported that CD without such symptoms can also have a negative influence on sleep quality and that skin unpleasant sensations aggravate SD. Further immunologic or neurologic clinical studies will be necessary to better understand the source of sleep abnormalities in patients with CD and to deepen our knowledge of the roles of the immune system, circadian rhythm, microbiota and environmental factors. Dermatologists need to incorporate the possible presence of an undiagnosed sleep disorder into their assessment of disease. It is important that dermatologists ask general questions about pruritus, pain, intermediate sensations, and sleep with patients during routine evaluations of cutaneous disorder. Kaaz et al38 proposed reliable guidelines concerning the evaluation and management of sleep disorders in chronic dermatological patients.